文献速递类风湿关节炎

难治性类风湿关节炎中患者与医生的评估:b/tsDMARD治疗早期主观感知的模式

Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment.
PubMed 文献 · RMD Open · 2023-01-01

该纵向研究纳入2020至2022年255例类风湿关节炎患者,按EULAR定义分为NoD2TRA 167例、D2TRA-inefficacy 58例和D2TRA-other 30例。采用潜类别混合模型分析b/tsDMARD治疗前24个月内每6个月收集的DAS28、PGA和PhGA轨迹。结果显示DAS28和PhGA各分2种轨迹、PGA分3种轨迹,变化主要发生在治疗前6个月;多数D2TRA-inefficacy患者归入数值较高的轨迹,NoD2TRA归入数值较低的轨迹,而D2TRA-other在各轨迹中分布较均匀。

要点

  • DAS28和PhGA各识别出2种轨迹,PGA识别出3种轨迹
  • 各指标最明显的变化出现在b/tsDMARD治疗前6个月,之后随访期保持稳定
  • 多数D2TRA-inefficacy患者归入数值较高的轨迹,NoD2TRA归入数值较低的轨迹

核心结论

  • 疾病活动度评估结合患者与医生的主观感知,是正确区分将发展为D2TRA-inefficacy患者的关键要素。
  • 无论采用主观还是客观参数,识别将发展为D2TRA-other的患者仍然具有挑战性。

研究设计与样本

  • 纵向研究,纳入2020至2022年255例类风湿关节炎患者。
  • 按EULAR的D2TRA定义分为NoD2TRA 167例、D2TRA-inefficacy 58例和D2TRA-other 30例。
  • 采用潜类别混合模型分析b/tsDMARD治疗前24个月内每6个月收集的DAS28、PGA和PhGA评分轨迹。

主要发现

  • 按最稳定模型,潜类别混合模型将DAS28和PhGA各分为2种轨迹,将PGA分为3种轨迹。
  • 最明显的变化出现在治疗前6个月,此后在整个随访期保持稳定。
  • 多数D2TRA-inefficacy患者归入数值较高的轨迹,NoD2TRA归入数值较低的轨迹,D2TRA-other在各轨迹中分布较均匀。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the trajectories of Disease Activity Score 28 (DAS28), patient global assessment (PGA) and physician global assessment (PhGA) and to assess their predictive capabilities on difficult-to-treat rheumatoid arthritis (D2TRA) classification. METHODS: Longitudinal study of patients with rheumatoid arthritis (RA) from 2020 to 2022. Based on the D2TRA EULAR (European Alliance of Associations for Rheumatology) definition, patients were classified as D2TRA according to biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) failure due to inefficacy (D2TRA-inefficacy) or other reasons (D2TRA-other). Patients who did not fulfil the D2TRA criteria were classified as NoD2TRA. DAS28, PGA and PhGA scores collected every 6 months during the first 24 months of b/tsDMARD treatment were used to identify different trajectories using latent class mixed models (LCMM). RESULTS: The study population comprised 255 patients with RA, of whom 167 were NoD2TRA, 58 D2TRA-inefficacy and 30 D2TRA-other. LCMM stratified patients into two different trajectories for DAS28 and PhGA and three for PGA according to the most stable model. The most notable variation occurred during the first 6 months of treatment, thereafter remaining stable during the follow-up period. Most D2TRA-inefficacy patients fitted the trajectory, showing higher values of the studied parameters. NoD2TRA followed the trajectory with lower values, and D2TRA-other were distributed more homogeneously across all trajectories. CONCLUSIONS: The assessment of disease activity, together with patients' and physicians' perceptions, form a key element in the correct discrimination of patients who are going to develop D2TRA-inefficacy. However, identifying those patients who will be D2TRA-other remains challenging, whether by subjective or objective parameters.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Novella-Navarro M, Cabrera-Alarcón J, López-Juanes N, et al. Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment. RMD Open. 2023. PMID: 37775112. doi:10.1136/rmdopen-2023-003382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。